Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Core SG&A: -$13,238M in FY2025, up 5.4% from a year earlier. That is the lowest of the 9 years on record here.
Latest, FY2025
-13,238
Period ended Dec 31, 2025
Change on a year earlier
+5.4%
-12,564 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Where the FY2025 figure comes from
“|| Selling, general and administration | -13 248 | 10 | -13 238 | -12 564”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core SG&A ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -13,238 | +5.4% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | -12,564 | +637.8% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | -1,703 | -16.8% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | -2,047 | +295.2% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | -518 | -95.5% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | -11,583 | +1,756.3% | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2019 | Dec 31, 2019 | -624 | -77.2% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | -2,739 | +8.2% | Novartis Form 6-K (0001370368-19-000006) ↗ |
| FY2017 | Dec 31, 2017 | -2,532 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Cite this data
StockData. (2026). Novartis Core SG&A ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-sga
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.